NCT04026711

MitoQ for the Treatment of Metabolic Dysfunction in Asthma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: University of Vermont · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A 14-week, randomized, placebo-controlled, double-masked clinical trial in 40 obese patients with poorly controlled asthma. The intervention is Mitoquinol (MitoQ) versus placebo. The primary aim of this pilot study is to determine if MitoQ improves airway reactivity in obese patients with asthma.

Detailed description

Study aim: The objective of this proposal is to conduct a pilot clinical trial to determine if the mitochondrial-targeted anti-oxidant MitoQ improves airway reactivity in obese patients with poorly controlled asthma. Type of Study: A 14 weeks, prospective, two center (Duke and the University of Vermont), randomized, placebo-controlled, double-masked clinical trial. Study Population: 40 patients with obesity and poorly controlled asthma. Intervention: MitoQ 40 mg per day versus placebo.

Conditions

• Asthma
• Obesity

Interventions

Type	Name	Description
DRUG	Mitoquinol	Mitoquinol (MitoQ) 40 mg per day for 12 weeks
DRUG	Placebo oral tablet	Placebo daily for 12 weeks

Timeline

• Start date: 2020-01-01
• Primary completion: 2024-03-31
• Completion: 2024-03-31
• First posted: 2019-07-19
• Last updated: 2025-12-11
• Results posted: 2025-12-11

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study